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Abstract
Introduction: Given the role of estrogen in breast carcinogenesis and the modification of estrogen receptor (ER)
activity by its biochemical cofactors, we hypothesize that genetic variation within ER cofactor genes alters cellular
response to estrogen exposure and consequently modifies the risk for ER-positive breast cancer.
Methods: We genotyped 790 tagging SNPs within 60 ER cofactor genes in 1,257 cases and 1,464 controls from
Sweden and in 2,215 cases and 1,265 controls from Finland, and tested their associations with either ER-positive or
ER-negative breast cancer.
Results: Seven SNPs showed consistent association with ER-positive breast cancer in the two independent
samples, and six of them were located within PPARGC1B, encoding an ER co-activator, with the strongest
association at rs741581 (odds ratio = 1.41, P = 4.84 × 10
-5) that survived Bonferroni correction for multiple testing
in the combined ER-positive breast cancer sample (Pcorrected = 0.03). Moreover, we also observed significant
synergistic interaction (Pinteraction = 0.008) between the genetic polymorphisms within PPARGC1B and ESR1 in ER-
positive breast cancer. By contrast, no consistent association was observed in ER-negative breast cancer.
Furthermore, we found that administration of estrogen in the MCF-7 cell line induced PPARGC1B expression and
enhanced occupancies of ER and RNA polymerase II within the region of SNP association, suggesting the
upregulation of PPARGC1B expression by ESR1 activation.
Conclusions: Our study revealed that DNA polymorphisms of PPARGC1B, coding a bona fide ER co-activator, are
associated with ER-positive breast cancer risk. The feed-forward transcriptional regulatory loop between PPARGC1B
and ESR1 further augments their protein interaction, which provides a plausible mechanistic explanation for the
synergistic genetic interaction between PPARGC1B and ESR1 in ER-positive breast cancer. Our study also highlights
that biochemically and genomically informed candidate gene studies can enhance the discovery of interactive
disease susceptibility genes.
Introduction
It is known that the risk of breast cancer is related to
lifetime exposure to estrogen [1,2]. Estrogen stimulates
cell proliferation and increases the frequency of sponta-
neous mutations, leading to a malignant phenotype [3].
Breast cells respond to estrogen via estrogen receptors
(ERs) through a defined biochemical process: upon
ligand binding, ERs undergo a conformational change
that facilitates receptor dimerization, DNA binding,
recruitment of ER cofactors, and modulation of target
gene expression [4-6].
Endocrine therapy provides strong evidence that
attenuation of ER (ESR1) activity can reduce breast can-
cer risk [7], and women with ER-positive tumor would
be the most likely to benefit from these treatments [7,8].
The genetic studies of ESR1,h o w e v e r ,h a v eh a d
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any medium, provided the original work is properly cited.contradictory results. Only recently, through a very large
genetic association study, has there been demonstrated a
small but significant association of polymorphisms
within ESR1 with the risk of breast cancer [9-11]. Two
plausible explanations for the inconsistent results might
be due to the small sample sizes and thus limited statis-
tical power of these studies, or that the risk was not
evaluated by stratifying breast cancer patients based on
tumor ER status. However, there is at least one further
possibility: ER cofactors can either enhance transcrip-
tional activity of ER as co-activators or inhibit the activ-
i t ya sc o - r e p r e s s o r s .T h eg e n e t i cv a r i a n t sw i t h i nE R
cofactors have not been systematically investigated in
term of association with breast cancer risk, although
some coding variants within individual genes, such as
NCOA3 and CCND1, have been investigated [12-15].
Given the modification of ER activity by its cofactors
through their physical and functional interactions [16],
the cofactor proteins that bind to ER may be as impor-
tant as the receptor itself in mediating transcriptional
response to estrogen exposure [17]. We therefore
hypothesized that genetic variation within ER cofactor
genes may alter cellular response to estrogen exposure
and consequently, alone or by interacting with genetic
variations within ESR1, modify breast cancer risk in an
ER status-dependent fashion. To assess this hypothesis,
we investigated the association of common genetic var-
iation, using a tagging SNP approach, within 60 cofactor
genes in two large case-control samples of breast cancer
from Sweden and Finland, and investigated their inter-
action with genetic variation within ESR1 in terms of
influencing the risk of hormone-driven breast cancer.
Materials and methods
Study population
The Swedish sample was from a population-based case-
control study that has been described in detail pre-
viously [18]. Briefly, 1,322 cases were Swedish-born
women diagnosed with incident primary invasive breast
cancer between October 1993 and March 1995 who
contributed blood samples. All cases were postmeno-
pausal and between 50 and 74 years of age at diagnosis.
All the cases were identified through the six regional
cancer registries in Sweden. The controls (n = 1,524)
were randomly selected from the Swedish Registry of
Total Population with no previous breast cancer and
were frequency-matched for age with the cases. Ques-
tionnaires were used to collect risk factor information.
The Finnish sample was from a hospital-based case-
control study in which the cases consisted of two series
of unselected breast cancer patients and additional
familial patients diagnosed at the Helsinki University
Central Hospital. The first set of cases were 884 patients
collected in 1997/1998 and 2000, covering 79% of all
newly diagnosed breast cancer cases during those peri-
ods [19,20]. The second set of cases, consisting of 986
newly diagnosed breast cancer patients, were collected
during 2001 to 2004 and covered 87% of all such
patients during that period [21]. An additional 538
familial breast cancer cases were also collected at the
same hospital, as previously described [22,23]. Women
with a prior diagnosis of breast cancer in situ were
excluded, leaving 2,215 invasive breast cancer cases for
analysis. Healthy female population controls (n = 1,287)
were collected from the same geographical regions of
Finland as the cases.
Information on reproductive and hormonal risk fac-
tors was available for the Swedish sample and showed
expected association patterns with breast cancer [24-26].
Such information was not available for the Finnish
controls.
Hormone receptor status information was retrieved
from medical records of all participating cases and was
available for both the Swedish and Finnish cases.
Approval for the study was obtained from the Institu-
tional Review Boards in Sweden, Finland and the
National University of Singapore. All subjects provided
written informed consent.
DNA isolation
DNA was extracted from 4 ml whole blood using the
QIAamp DNA Blood Maxi Kit (Qiagen, Hilden, Ger-
many) according to the manufacturer’s instructions.
Candidate gene and tagging SNP selection
In the present study, the keywords ‘ER cofactor’, ‘ER
coactivator’ and ‘ER corepressor’ were used in a litera-
ture search to identify ER cofactor genes. Boolean
searching (’AND’‘ OR’) was used to narrow or broaden
the search in PubMed. Using this method, 60 ER cofac-
tor genes were identified as candidate genes. Tagging
SNPs within the 60 candidate genes were selected based
on the HapMap CEU data (Rel #22/phase II Apr07, on
NCBI B36 assembly, dbSNP b126) [27]. In brief, for
each gene, all common SNPs with a minor allele fre-
quency >0.05 within the gene and 5 kb surrounding
region were first identified from the HapMap database
[28]. Tagging SNPs were then selected in Haploview
version 4.1 [29] using a pair-wise SNP tagging approach
with r
2 > 0.8 used as the criterion for selection. A total
of 806 tagging SNPs were selected within the 60 ER co-
factor genes.
Genotyping
Illumina’s GoldenGate assay was used for genotyping
SNPs, following the manufacturers’ instructions (Illu-
mina, San Diego, CA, USA). In brief, all 806 tagging
SNPs were subjected to genotyping assay design, out of
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jected to genotyping analysis. DNA samples were ran-
domly assigned to the plates carrying positive and
negative controls, and all genotyping results were gener-
ated and checked by laboratory staff unaware of the
case-control status. SNPs with a call rate <96% (81
SNPs failed in the Swedish sample and 42 SNPs failed
in the Finnish sample) and minor allele frequency <1%
(18 SNPs in the Swedish sample and 40 SNPs in the
Finnish sample) were excluded from further analysis.
Deviation of genotype frequencies from those expected
under Hardy-Weinberg Equilibrium were assessed in the
control subjects. SNPs with Hardy-Weinberg Equili-
brium P <7 . 4×1 0
-5 (0.05/675) were excluded (6 SNPs
failed in the Swedish sample and 15 SNPs failed in the
Finnish sample). In total, 685 SNPs from the Swedish
sample and 693 SNPs from the Finnish sample were
used for statistical analysis, and 675 shared SNPs
between the Swedish and Finnish samples were used for
analysis in the combined sample.
Genotyping was duplicated in 2% of samples (in both
Swedish and Finnish samples) and there was concor-
dance in >99% of the duplicated samples, suggesting
high genotyping accuracy. With r
2 > 0.8, the average
coverage of common variation (minor allele frequency
>5%) within the 60 candidate genes was 91%. Out of
these, 51 genes had coverage over 80% (Additional file 1
Table S1).
Reverse transcriptase-quantitative PCR analysis
MCF-7 cells were cultured in DMEM (Invitrogen, Carls-
bad, CA, USA) medium with 10% FBS (Invitrogen).
Prior to hormone treatment, cells were maintained in
phenol-red free DMEM F-12 containing 5% charcoal
stripped serum for 72 hours for hormone depletion.
Cells were treated with 10 nM 17b-estradiol (Sigma-
Aldrich, St. Louis, MO, USA) for a period of 0 or 3
hours. Cells were harvested and total RNA and reverse
transcriptase-quantitative PCR analysis was carried out
as described previously [30]. Dimethylsulfoxide (Sigma-
Aldrich, St. Louis, MO, USA)/vehicle-treated cells were
used as controls for the same time course. Real-time
PCR analysis was performed in the ABI Prism 7700
sequence detection system using SYBR Green from ABI
(Applied Biosystems, Foster City, CA,USA).
Primers were designed using the online Primer 3 pro-
gram [31]. All experiments were repeated at least twice.
Two sets of primers were used for identifying different
isoforms of PPARGC1B. The oligonucleotide sequences
were as follows: PPARGC1B_1 isoform (NM_00117
2699.1) forward 5’-GAAGAGGAAGAAGGGGAGGA-3’
and reverse 5’-CTCTGGTAGGGGCAGTGGT-3’;a n d
PPARGC1B_2 isoform (NM_133263.3) forward 5’-
CCTGAAGATGACGTGGGTCT-3’ and reverse 5’-
CCTTCCTTCTGGGTGTCAGA-3’. b-Actin specific pri-
mers (forward 5’-TCCCTGGAGAAGAGCTACGA-3’
and reverse 5’-AGGAAGGAAGGCTGGAAGAG-3’)
were used as an internal control to normalize the
amounts of reverse transcribed product used in the PCR
reaction. Threshold cycle (Ct) values obtained for
PPARGC1B isoforms were normalized to b-actin Ct
values. The normalized Ct (ΔCt) values were then used
to calculate the difference (ΔΔCt) between estradiol-
treated and dimethylsulfoxide-treated samples. The fold
change of PPARGC1B was calculated as 2
-ΔΔCt.
Statistical analysis
To measure the magnitude of association between SNPs
and breast cancer risk, per-allele odds ratios (ORs)
(assuming a log-additive model) and 95% confidence
intervals were estimated using logistic regression. As the
controls were younger than cases in the Finnish sam-
ples, age at diagnosis/enrollment (as a continuous vari-
able) was included in the regression models in the
Finnish analysis for OR adjustment. The Cochran-Armi-
tage trend test was used to calculate P values in the
Swedish and Finnish sample sets, separately in subtypes,
and in cases overall. Inverse variance weighting was
used in a meta-analysis for two independent datasets.
The individual OR was obtained from age-unadjusted
analysis in the Swedish sample and age-adjusted analysis
in the Finnish sample. To evaluate differences in ORs
between studies, a test of homogeneity was carried out
for each individual SNP analysis (data not shown).
To determine the model of inheritance, associations
between SNPs within the PPARGC1B gene and ER-posi-
tive breast cancer risk were estimated by assuming
dominant, recessive and additive models in the two
sample sets. We then performed these analyses with
meta-analysis using inverse variance weighting approach.
Individual ORs from two independent studies followed-
up age-unadjusted analysis in the Swedish sample and
age-adjusted analysis in the Finnish sample.
Forward stepwise logistic regression was used to
explore whether the associations at the six SNPs were
independent of each other. The selection criterion was
P < 0.2. The analysis was performed in ER-positive
breast cancer risk in the two sample sets separately as
well as in the combined ER-positive sample dataset. To
account for different minor allele frequencies in the two
populations, a binary indicator variable for study was
included in the regression models as well as age in the
combined data regression analysis.
Pair-wise interaction analysis was performed under a
dominant mode of inheritance using logistic regression
and likelihood ratio tests. To maximize the statistical
power, we pooled sample sets from the Swedish and
Finnish data. Age and study were included in the model
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term between the two interacting variables for the risk
of breast cancer. In this multiv a r i a t el o g i s t i cr e g r e s s i o n
analysis, each coefficient provided an estimate of the log
OR whilst adjusting for all other variables included in
the model. Likelihood ratio tests, comparing models
with and without the interaction term, were used to
generate P values.
All analyses were performed using STATA version 8.0
(StataCorp, College station, TX, USA). Linkage disequili-
brium (LD) calculation was performed in Haploview
version 4.1 [29]. All statistical tests were two-sided.
Results
Study subjects
Two independent case-control samples of breast cancer
from Sweden and Finland were investigated in the present
study, whose characteristics are summarized in Table 1.
The cases and controls of the Swedish sample were fre-
quency-matched on age, whereas the Finnish controls
were younger than the Finnish cases (P < 0.0001). In the
Swedish sample, there were significant differences between
the cases and controls in terms of age at first birth (P =
0.0002), age at menopause (P = 0.0001), hormone replace-
ment treatment use (P = 0.017), and parity (P = 0.0001),
which is consistent with the well-established role of these
reproductive factors in breast cancer development. The
reproductive factor information was not available for the
Finnish controls. In both the Swedish and Finnish cases,
there were similar percentages of ER-positive (81.9% vs.
80.9%) and ER-negative (18.1% vs. 19.1%) cases.
SNP association analysis
First, single SNP association analyses were performed
using trend tests in the Swedish and Finnish samples
separately by stratifying the cases into ER-positive and
ER-negative groups, with 685 SNPs being tested in the
Swedish sample and 693 SNPs being tested in the Fin-
nish sample. 48 SNPs (7.00%) in the Swedish sample
and 50 SNPs (7.28%) in the Finnish sample showed
association with ER-positive breast cancer risk with
nominal P < 0.05. Seven SNPs showed consistent asso-
ciation between the two independent samples (Addi-
tional file 1 Table S2), and six of them were located
within the PPARGC1B gene. In contrast, 21 and 50
SNPs showed association with ER-negative breast cancer
with nominal P < 0.05 in the Swedish and Finnish sam-
ples, respectively, but no SNPs showed consistent asso-
ciations between the two independent samples.
We then analyzed SNP associations in the combined
Swedish and Finnish samples. In general, SNPs showed
stronger evidence of association with ER-positive breast
cancer than ER-negative breast cancer (Table 2; see also
Additional file 1 Table S3). The most significant associa-
tion was identified at rs741581 within the second intron
of PPARGC1B (OR = 1.41, P =4 . 8 4×1 0
-5)i nE R - p o s i -
tive breast cancer, which survived the Bonferroni correc-
tion for multiple testing (Pcorrected = 0.03). rs741581 was
one of the seven SNPs that showed consistent associa-
tions between the Swedish and Finnish samples.
We also evaluated the SNP association with overall
breast cancer risk and found 55 SNPs (8.03%) from the
Swedish samples and 61 SNPs (8.80%) from the Finnish
samples to show association with overall breast cancer risk
with nominal P < 0.05. Only two SNPs, however, showed
consistent association between the two independent sam-
ples (Additional file 1 Table S2), and none of the associa-
tions survived Bonferroni correction for multiple testing in
the combined samples (smallest Pcorrected =0 . 1 9 8 ) .
Genotype association analysis of PPARGC1B in ER-positive
breast cancer
PPARGC1B is located on 5q33.1 and encodes for peroxi-
some proliferative activated receptor gamma coactivator
Table 1 Selected characteristics of cases and controls in the Swedish and the Finnish samples
Swedish sample Finnish sample
Characteristic Number Mean P value
a Number Mean P value
a
Entire study
Age (years) 1,257/1,464 63.11/63.12 0.96 2,214/1,265 56.07/40.88 < 1.00 × 10
-4
Age at first birth 1,072/1,321 25.50/24.76 2.00 × 10
-4 1,185/- 26.43/- /
Age at menopause 1,247/1,460 50.6/49.97 1.00 × 10
-4 1,341/- 50.34/- /
BMI (recent) 1,250/1,443 25.71/25.67 0.81 1,525/- 25.03/- /
Number Percentage Number Percentage
Case only
All cases 1,257 / 2,215 /
ER-positive 684 81.92 1,709 80.92
ER-negative 151 18.08 403 19.08
Controls 1,464 / 1265 /
Data presented as cases/controls. BMI, body mass index; ER, estrogen receptor.
aTwo-sided t test was used for P value estimation.
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In the present study, 40 tagging SNPs within
PPARGC1B were successfully genotyped in both the
Swedish and Finnish samples, which could capture 80%
of common variants (131 out of 162 SNPs) within
PPARGC1B with a minimal r
2 value of 0.8 (mean r
2
value = 0.95, according to HapMap CEU data).
To have a better understanding of the association
within PPARGC1B, we performed genotype-based asso-
ciation analysis by assuming dominant, recessive and
additive model of inheritance. We found that the top
three SNPs yielding the most significant association evi-
dence in the dominant model compared with other
models (Additional file 1 Table S5). Under the dominant
model, the same six SNPs (as for the trend tests) of the
40 SNPs within PPARGC1B showed consistent associa-
tion with ER-positive breast cancer between the Swedish
and Finnish samples (Table 3). The strength of the asso-
ciation (ORs) at the six SNPs was stronger in ER-posi-
tive breast cancer than in overall or ER-negative
cancers, with the strongest association identified at
rs741581 (P =1 . 9×1 0
-2 in the Swedish samples, P =
6.1 × 10
-5 in the Finnish samples, and P =1 . 8×1 0
-5 in
the combined samples).
The six SNPs showing consistent association with
ER-positive breast cancer were located within two
regions of high LD (Figure 1B), suggesting that the
associations at those SNPs may not be completely
independent. We therefore performed a forward step-
wise logistic regression (cut-off P = 0.20) and revealed
two independent associations with ER-positive breast
cancer at rs741581 (P = 0.031) and rs6895698 (P =
0.014) in the combined sample. Under the dominant
model, we found that rs741581, rs6895698, age and
study sample were four independent variables asso-
ciated with ER-positive breast cancer risk. Similarly,
the same stepwise analysis of ER-positive breast cancer
in the two individual samples also revealed two inde-
pendent associations at rs741581 (P = 0.172) and
rs2340621 (P = 0.036) in the Swedish sample and at
rs741581 (P = 0.023) and rs6895698 (P = 0.053) in the
Finnish sample. Notably, rs6895698 and rs2340621 lie
within the same LD block and are highly correlated
(r
2 = 0.72, according to HapMap CEU data).
Table 2 Twenty-five most significant SNPs associated with ER-positive breast cancer in Swedish and Finnish samples
Gene SNP Position P value
a Adjusted P value
b OR (95% CI)
a
PPARGC1B rs741581
cd chr5:149182978 4.84 × 10
-5 0.033 1.414 (1.197, 1.672)
PPARGC1B rs1012543
cd chr5:149157138 9.98 × 10
-5 0.067 1.223 (1.105, 1.353)
PPARGC1B rs6895698
d chr5:149120455 2.73 × 10
-4 0.184 1.225 (1.098, 1.366)
CARM1 rs1529711 chr19:10884434 4.26 × 10
-4 0.288 1.229 (1.096, 1.378)
RBM23 rs7469
c chr14:22440037 1.15 × 10
-3 0.778 1.248 (1.092, 1.427)
PPARGC1B rs4705365
cd chr5:149093146 1.78 × 10
-3 - 1.193 (1.068, 1.333)
NCOR2 rs10846670 chr12:123456184 2.67 × 10
-3 - 0.872 (0.798, 0.954)
RBM23 rs3811187
c chr14:22439134 2.96 × 10
-3 - 1.158 (1.051, 1.275)
PELP1 rs4790674 chr17:4529772 3.23 × 10
-3 - 1.171 (1.054, 1.3)
PPARGC1B rs2340621
d chr5:149122509 4.00 × 10
-3 - 1.149 (1.045, 1.262)
CCND1 rs649392
cd chr11:69173974 4.43 × 10
-3 - 0.877 (0.801, 0.96)
PPARGC1B rs10036538
d chr5:149135781 5.51 × 10
-3 - 1.156 (1.043, 1.28)
PELP1 rs7214635 chr17:4547769 5.67 × 10
-3 - 1.166 (1.046, 1.3)
PPARGC1B rs4705382 chr5:149161559 6.32 × 10
-3 - 0.872 (0.791, 0.962)
NEDD4 rs11071224
c chr15:53902817 6.32 × 10
-3 - 0.764 (0.63, 0.927)
MED13 rs4968469
c chr17:57491867 6.90 × 10
-3 - 1.145 (1.038, 1.263)
NCOR2 rs12321007 chr12:123449054 7.44 × 10
-3 - 1.137 (1.035, 1.25)
MED13 rs9889324
c chr17:57481404 8.89 × 10
-3 - 1.14 (1.033, 1.258)
NCOR2 rs1794973 chr12:123391545 9.45 × 10
-3 - 0.889 (0.813, 0.972)
PPARGC1B rs1422429 chr5:149146627 1.11 × 10
-2 - 1.124 (1.027, 1.231)
NCOR2 rs10846666 chr12:123450306 1.17 × 10
-2 - 0.867 (0.776, 0.969)
NCOA1 rs17046513 chr2:24817999 1.26 × 10
-2 - 1.284 (1.055, 1.563)
NCOA1 rs17046462 chr2:24759054 1.37 × 10
-2 - 1.285 (1.053, 1.568)
NCOR2 rs10846667 chr12:123450377 1.40 × 10
-2 - 0.895 (0.819, 0.978)
SNW1 rs3759728
c chr14:77299912 1.49 × 10
-2 - 0.855 (0.753, 0.97)
ER, estrogen receptor; chr, chromosome; OR, odds ratio; CI, confidence interval.
aP value and OR were obtained from meta-analysis based on the inverse variance
method for two independent datasets. The individual OR was obtained from age-unadjusted analysis in the Swedish sample and age-adjusted analysis in the
Finnish sample.
bP value was adjusted by Bonferroni correction (n = 675); -, adjusted P >1 .
cSNP belongs to the top 25 most significant SNPs associated with ER-
negative breast cancer.
dSNP was significantly associated with ER-positive breast cancer in both the Swedish and Finnish datasets.
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cancer
Our previous study suggested an association between
ESR1 polymorphisms and breast cancer risk [9,32] in
the same Swedish sample. The association was within a
region flanked by rs988328 to rs3020318 and was mani-
fested by three haplotypes. Using the haplotype informa-
tion from the HapMap CEU data, we identified three
common SNPs that were in high LD (r
2 = 0.89) with
one of the three haplotypes (TAG18~21) [9], while no
SNPs were found with r
2 > 0.5 for the other two haplo-
types, based on the HapMap CEU data (Rel #22/phase
II Apr07, on NCBI B36 assembly, dbSNP b126). Given
that the three SNPs were in perfect LD (r
2 =1 ) ,w e
genotyped one of the three SNPs, rs7761846, in our
Swedish and Finnish samples. Given that a large associa-
tion study of ESR1 by the Breast Cancer Association
Consortium also revealed a significant association within
t h es a m er e g i o nu n d e rad o m i n a n tm o d e l[ 1 0 ] ,w e
searched for SNPs that were in high LD (r
2 >0 . 5 )w i t h
the three haplotypes but were not genotyped in our pre-
vious study. Then we performed a genotype-based asso-
ciation analysis under a dominant model of inheritance.
As expected, rs7761846 showed association with ER-
positive breast cancer (OR = 1.28, P = 0.014) in the
combined sample. The two independent Swedish and
Finnish samples also revealed consistent association,
although the association in the Finnish sample did not
reach statistical significance (Table 4).
Genetic interaction between the polymorphisms of
PPARGC1B (rs6895698, rs2340621 and rs741581) and ESR1
(rs7761846)
G i v e nt h ek n o w nm o d i f i c a t i o no fE Ra c t i v i t yb y
PPARGC1B in cellular response to estrogen exposure, we
investigated the genetic interaction between rs741581,
rs2340621 and rs6895698 within PPARGC1B and
rs7761846 within ESR1 in terms of modulating ER-posi-
tive breast cancer risk. The analysis in the combined
sample identified a significant synergistic interaction
between rs2340621 (representing PPARGC1B)a n d
rs7761846 (representing ESR1)( Pinteraction = 0.008)
(Table 5). Women carrying both PPARGC1B (rs2340621)
and ESR1 (rs7761846) risk genotypes (GA/AA and CT/
CC) had a much higher risk for breast cancer than non-
carriers (GG and TT)( O R=1 . 9 4 ,P =2 . 0 3×1 0
-6). Simi-
lar patterns of genetic interaction were also observed
between the remaining SNPs rs741581 (PPARGC1B)a n d
rs7761846 (ESR1) as well as rs6895698 (PPARGC1B)a n d
rs7761846 (ESR1), although these interactions did not
achieve statistical significance - probably due to the low
minor allele frequencies of rs741581 and rs6895698.
However, the significant genetic interactions could not
be detected in overall or ER-negative breast cancer
(Additional file 2, Tables S6 and S7).
Transcriptional regulation of PPARGC1B by ERa
To understand the molecular mechanism underlying the
observed genetic interaction, we investigated whether
Table 3 Six overlapping SNPs in PPARGC1B associated with ER-positive breast cancer in Swedish and Finnish samples
SNP Allele
a Subtype Swedish sample Finnish sample
MAF
b OR
c (95% CI) MAF
b OR
c (95% CI)
rs4705365 G/A ER+ 0.21 1.26 (1.05, 1.52) 0.17 1.26 (1.05, 1.52)
ER- 1.14 (0.81, 1.61) 1.17 (0.9, 1.52)
All cases 1.14 (0.97, 1.33) 1.18 (0.99, 1.4)
rs6895698 G/A ER+ 0.22 1.27 (1.06, 1.53) 0.17 1.39 (1.15, 1.67)
ER- 1.05 (0.74, 1.48) 1.14 (0.88, 1.49)
All cases 1.12 (0.96, 1.3) 1.25 (1.05, 1.49)
rs2340621 G/A ER+ 0.31 1.3 (1.08, 1.57) 0.32 1.22 (1.03, 1.46)
ER- 0.86 (0.61, 1.2) 1.05 (0.82, 1.34)
All cases 1.12 (0.96, 1.31) 1.14 (0.97, 1.34)
rs10036538 C/G ER+ 0.26 1.19 (0.99, 1.42) 0.22 1.2 (1, 1.43)
ER- 0.91 (0.65, 1.28) 1.05 (0.81, 1.35)
All cases 1.03 (0.89, 1.2) 1.11 (0.94, 1.31)
rs1012543 A/G ER+ 0.26 1.26 (1.05, 1.51) 0.23 1.26 (1.06, 1.5)
ER- 1.08 (0.77, 1.51) 1.08 (0.84, 1.38)
All cases 1.11 (0.95, 1.29) 1.18 (1, 1.39)
rs741581 G/A ER+ 0.08 1.32 (1.05, 1.67) 0.05 1.76 (1.33, 2.31)
ER- 0.81 (0.49, 1.32) 1.21 (0.81, 1.82)
All cases 1.12 (0.92, 1.37) 1.53 (1.18, 1.98)
ER+, estrogen receptor-positive; ER-, estrogen receptor-negative; MAF, minor allele frequency; OR, odds ratio; CI, confidence interval.
aMajor allele/minor allele.
bFrom control samples only.
cORs were performed on a dominant model, age-unadjusted analysis in the Swedish sample and age-adjusted analysis in the Finnish
sample.
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SNPs
Recombination Rate
ER occupancy with E2 Treatment
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rs4705365
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rs1012543
rs741581
ER ChIA-PET interactions
PolII occupancy without E2 Treatment
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I
Figure 1 Transcriptional regulation of PPARGC1B by estrogen receptor alpha in the MCF7 cell line. (A) Schematic diagram of the genes
from the UCSC database. (B) Map positions of six significant SNPs within PPARGC1B. (C) Recombination rate surrounding PPARGC1B from the
HapMap CEU database. (D) MCF7 input DNA density for chromatin immunoprecipitation-sequencing (CHIP-seq) analysis. (E) CHIP-seq RNA PolII
occupancy density without 17b-estradiol (E2) treatment. (F) CHIP-seq estrogen receptor (ER) occupancy without E2 treatment. (G) CHIP-seq RNA
PolII occupancy density with E2 treatment. (H) CHIP-seq ER occupancy with E2 treatment. (I) ER interaction loop detected by chromatin
interaction analysis by paired-end tag sequencing (ChIA-PET).
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Page 7 of 12there was any transcriptional cross-talk between the two
genes beyond the known ligand-dependent, co-activating
interaction of the PGC-1b with ERa [33,34], using the
ER-responsive MCF7 breast cancer cell line.
First, we examined the expression of PPARGC1B in
MCF7 and noted a twofold induction of PPARGC1B
expression by ER activation after estradiol administra-
tion (Additional file 3 Figure S1). As a marker of
transcriptional activity, chromatin immunoprecipitation-
sequencing analysis in the same MCF7 cell line identified
a significant peak of RNA polymerase II occupancy close
to the transcriptional start site of PPARGC1B within the
LD region of SNP association, and the RNA polymerase
II occupancy was further enhanced by estradiol treat-
ment. This observation confirms the transcriptional
responsiveness of PPARGC1B to estradiol. Moreover, the
chromatin immunoprecipitation-sequencing analysis also
identified five ER binding sites in and around PPARGC1B
(one site located approximately 50 kb 5’ of the transcrip-
tional start site, one in the second intron of the gene
within 13 kb of the associated SNP rs741581, and the
other three binding sites approximately 10, 31 and 57 kb
3’ of the polyadenylation signal sequence) and within the
LD region of significant association with ER-positive
breast cancer (Figure 1F). Interestingly, the sites showing
highest of ER occupancy were seen at two locations, one
~13 kb from the significant SNP rs741581 and the
second within 31 kb 3’ of the polyadenylation signal
sequence.
We recently described the identification of all ER
binding site interactions in the human genome [35,36]
and defined that genes engaged in chromatin loop for-
mation by a transcription factor were definitively regu-
lated by the factor. Our data indicated that all of the ER
binding sites around PPARGC1B were engaged in chro-
matin loop formation centered on the PPARGC1B gene
(Figure 1I), which indicates that ERa directly regulates
PPARGC1B.
Taken together, these data strongly indicate that
PPARGC1B expression could be directly regulated by
ERa and - when coupled with the known enhancement
of ERa transcriptional activity by the PGC-1b at the site
of binding - suggest a feed-forward regulatory loop
between the two genes that augments ER signaling
when the two factors are present.
Discussion
To our knowledge, this is the first comprehensive asso-
ciation analysis of common variation within ER cofac-
tor genes in breast cancer where 36 ER co-activators
and 24 ER co-repressors were investigated. The utiliza-
tion of two independent case-control samples of north-
ern European origin allowed us to identify an
association based not only on the overall significance
in the large combined sample, but also on the consis-
tency of the SNP association between the two indivi-
dual samples. We found significant associations
between PPARGC1B polymorphisms and risk for ER-
positive breast cancer, and, importantly, we revealed a
synergistic effect between the genetic polymorphisms
within PPARGC1B and ESR1.
Table 4 Association analysis of rs7761846 within ESR1
under a dominant model in ER-positive case analysis
Sample Control Case OR (95% CI) P value
Swedish 1,442 675 1.43 (1.10, 1.86) 0.007
Finnish 1,246 1669 1.10 (0.81, 1.48) 0.55
Combined
a 2,688 2344 1.28 (1.05, 1.56) 0.014
ER, estrogen receptor; OR, odds ratio; CI, confidence interval.
aCombined
analysis was performed on logistic regression adjusted by age and study.
Table 5 Pair-wise interaction between SNPs within PPARGC1B and ESR1 on ER-positive breast cancer in combined
Swedish and Finnish samples
ESR1 (rs7761846) PPARGC1B
Cases (%) Controls (%) OR (95% CI) Cases (%) Controls (%) OR (95% CI)
GG (rs2340621) GA/AA (rs2340621)
TT 916 (39) 1,121 (42) 1 1,160 (50) 1,280 (48) 1.18 (1.03, 1.34)
CT/CC 106 (5) 151 (6) 0.95 (0.71, 1.29) 161 (7) 134 (5) 1.94 (1.47, 2.55)
Interaction P value
a 0.008
GG (rs6895698) GA/AA (rs6895698)
TT 1,284 (55) 1,566 (58) 1 791 (34) 837 (31) 1.28 (1.11, 1.47)
CT/CC 160 (7) 184 (7) 1.21 (0.93, 1.55) 106 (5) 101 (4) 1.77 (1.30, 2.42)
Interaction P value
a 0.506
GG (rs741581) GA/AA (rs741581)
TT 1,741 (74) 2,076 (77) 1 335 (14) 326 (12) 1.41 (1.17, 1.70)
CT/CC 225 (10) 251 (9) 1.25 (1.01, 1.55) 42 (2) 34 (1) 2.18 (1.32, 3.59)
Interaction P value
a 0.459
OR, odds ratio; CI, confidence interval.
aAnalysis was performed on combined dataset, in which study and age were regarded as covariables.
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so far been limited. Burwinkel and colleagues reported a
significant association of coding variants Q586 H and
T960T of NCOA3 with familial breast cancer risk, and
further suggested that familial breast cancer patients may
condense the rare allele’s contribution to the protective
effect of breast cancer [12]. Whilst two studies have
reported an association of the variant Pro241Pro in
CCND1 with breast cancer risk [37,38], other studies
have reported negative results for this variant [14,39,40].
In particular, Wirtenberger and colleagues investigated
the coding variant Ala203Pro of PPARGC1B and found it
to be associated with familial breast cancer susceptibility
[41]. In our study, we did not observe significant associa-
tion between polymorphisms in NCOA3 and CCND1
with breast cancer risk. The Ala203Pro (rs7732671) var-
iant of PPARGC1B,h o w e v e r ,i s1 0k ba w a ya n dn o tc o r -
related with PPARGC1B SNP rs741581 (r
2 <0 . 0 5i n
HapMap CEU data), and thus would not have been
detected by our tagging SNP approach. Nevertheless,
both Wirtenberger and colleagues’ study and our study
support the association of genetic variation of
PPARGC1B with particular subtypes of breast cancer.
Importantly, the association of PPARGC1B as well as
its synergistic interaction with ESR1 was only observed
in breast cancer patients with ER-positive tumors, as
would be expected according to the biochemical
mechanism of interaction. There is growing evidence
that the impact of genetic risk factors on breast cancer
varies by hormone receptor status. For example, recent
studies by the Breast Cancer Association Consortium
have led to the discovery of novel breast cancer suscept-
ibility loci in FGFR2, TNRC9, 8q24, 2q35, and 5p12 that
showed stronger association with ER-positive disease
than with ER-negative disease [42-45], with fibroblast
growth factor receptor also being a direct target of ER.
These data suggest the risk of ER-positive tumors that
has been shown to be driven by reproductive factors in
epidemiologic studies also has a genomic basis based on
the constituents of the ER gene regulatory network
[46,47]. In our study, although the sample sizes of two
ER-positive datasets were smaller compared with the
two overall datasets, the number of overlapping SNPs
between the Swedish and Finnish studies was thus larger
than that observed in the overall breast cancer analysis.
Recently, we also demonstrated that genetic variation of
the estrogen metabolism pathway - particularly the
genes involved in the production of estrogen through
androgen conversion - also influences the risk for the
development of estrogen-sensitive breast cancer [48]. As
with this study, the effect size of the metabolism gene
polymorphisms are relatively small but, taken together
with PPARGC1B and fibroblast growth factor receptor,
show that the estrogen receptor signaling axis that
engages both upstream and downstream components
may have, in the composite, a significant role in the
genesis of the most common form of breast cancer.
The genetic interaction between PPARGC1B and ESR1
is biologically plausible. The PPARGC1B protein PGC-
1b is a bona fide ER co-activator [34] that physically
interacts with ERa and plays a role in amplifying ER sig-
naling, which provides a convincing biological mechan-
ism for the observed genetic interaction between the
two genes. Furthermore, our series of transcriptional
regulation analyses in the MCF7 ER-positive breast can-
cer cell line has demonstrated that PPARGC1B expres-
sion can be induced by estrogen treatment, and this
transcriptional response of PPARGC1B is probably
mediated by five functional ER binding sites around
PPARGC1B that are all engaged in interlocking chroma-
tin loops highly indicative of an ER regulated gene [35].
PPARGC1B may thus be involved in a feed-forward con-
trol mechanism with ERa such that ER induction (for
example, by estradiol treatment) heightens the expres-
sion of a co-activator PPARGC1B of ER, which in turn
increases ER action at the DNA binding site. The feed-
forward looping mechanism will therefore further aug-
ment the protein interaction between PPARGC1B and
ESR1. This putative amplification effect, if confirmed, is
another mechanistic model for epistatic interactions
between genetic loci and may be one reason for the
strength of its signal in the association study as com-
pared with the other ER cofactors studied.
There are some limitations to our study. Coverage of
common variation is not sufficient (< 80%) for some
genes (Additional file 1, Table S1), so that some associa-
tions may have been missed. In addition, our tagging
SNP selection provides a rather limited coverage of 5 kb
surrounding sequences of the candidate genes, which
may have contributed to some associations of regulatory
SNPs being undetected, such as the one reported within
ESR1 [11]. The number of overlapping SNPs between
the two datasets is small for both ER-positive and over-
all breast cancer analyses. The limited overlapping could
be due to ethnic heterogeneity between the two popula-
tion samples and their moderate sample sizes. On the
one hand, the ethnic heterogeneity may partially explain
the low overlapping SNPs between two datasets; on the
other hand, the current sample size is not large enough
to capture the moderate effect of associated SNPs. Some
of the top SNPs for each individual sample set are
therefore probably false positive, which causes the small
overlap between the numbers of significant SNPs in
both datasets. The sample size limitation in ER-negative
patients also could lead to the nonsignificant results in
ER-negative analysis, since we observed that some asso-
ciations in ER-negative analysis are in the same direc-
tion with ER-positive analysis. ER cofactors are known
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Page 9 of 12to work as a multicomponent protein complex, but due
to a sample size limitation we are unable to detect inter-
action among three or more genes simultaneously. It is
also worth noting that the contribution of genetic varia-
tion to cancer risk is based on both their prevalence and
penetrance, and thus the relative importance of indivi-
d u a lS N P sm a yv a r yf r o mp o p u l a t i o nt op o p u l a t i o n .
Further confirmation of our findings in other popula-
tions is therefore warranted.
Conclusions
Our study has revealed an association of genetic variation
within PPARGC1B with the risk of ER-positive breast can-
cer. Consistent with the known interaction of PPARGC1B
and ER at the molecular level, where PPARGC1B modu-
lates ER activity and thus ER signaling, our study revealed
a synergistic effect between genetic variation within the
PPARGC1B and ESR1 genes. PPARGC1B has been shown
to alter responses to the selective ER modulator, tamoxifen
[33]. Kressler and colleagues also demonstrated that
PPARGC1B indirectly co-activates tamoxifen-bound ERa,
which cooperates with NCOA1 to enable tamoxifen agon-
ism in kidney and osteosarcoma cell lines. Lastly, the
synergism demonstrated in the present study also suggests
that disrupting the interaction between an ER co-activator
- such as PPARGC1B - and ERa, or blocking their mutual
activation, may represent a sensitive and leveraged strategy
for cancer prevention [7]. Our study therefore provides
new biological insight into the genetic basis of the more
common ER-positive breast cancer and highlights that bio-
chemically and genomically informed candidate gene
study can enhance the discovery of interactive disease sus-
ceptibility genes.
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Additional file 1: Supplementary results of coverage evaluation of
common variants and association analysis in ER cofactor genes.
Table S1 presenting coverage evaluation of the common variant in 60 ER
cofactor genes. Table S2 presenting ORs and P values of the consistent
SNPs between the Swedish and Finnish samples from the analyses of ER-
positive and overall breast cancer. Table S3 presenting the 25 most
significant SNPs in ER-negative association analysis in Swedish and
Finnish samples. Table S4 presenting the 25 most significant SNPs in
overall association analysis in Swedish and Finnish samples. Table S5
presenting the comparison of P value among additive, dominant and
recessive models in the analysis of ER-positive breast cancer in PPARGC1B
in the combined Swedish and Finnish samples.
Additional file 2: Analysis of the pair-wise interaction effect
between SNPs within PPARGC1B and ESR1 on the overall and ER-
negative breast cancer in the combined Swedish and Finnish
samples. Table S6 presenting analysis of the pair-wise interaction effect
between SNPs within PPARGC1B and ESR1 on the overall breast cancer in
the combined Swedish and Finnish samples. Table S7 presenting the
analysis of pair-wise interaction effect between SNPs within PPARGC1B
and ESR1 on the ER-negative breast cancer in the combined Swedish
and Finnish samples.
Additional file 3: Relative expression of PPARGC1B gene in MCF7
cells 3 hrs post E2 treatment. Figure S1 presenting a relative
expression of the PPARGC1B gene in MCF7 cells 3 hours post 17b-
estradiol treatment.
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